Axsome bounces back as FDA clears depression drug
pharmaphorum
AUGUST 21, 2022
It is the first and only oral NMDA receptor antagonist to be approved for this use, and the first oral therapy with a new mechanism of action in around 60 years, said Axsome. Axsome acquired rights to the product in May, and reported almost $9 million in sales in the second quarter. Photo by Sydney Sims on Unsplash.
83 
Let's personalize your content